Eruptive nevi of the palms and soles

doi:10.1016/j.jaad.2004.08.009

Journal of the American Academy of Dermatology

Volume 52, Issue 5, Supplement, May 2005, Pages S96-S100

https://doi.org/10.1016/j.jaad.2004.08.009 Get rights and content

The sudden eruption of atypical and benign melanocytic nevi has been associated with a number of disease states and primary skin conditions. Most case reports and series of patients have linked eruptive nevi with blistering skin disease or immunosuppression. Subsets of patients in the immunosuppressed category have remarkably increased numbers of nevi on the palms and soles. We describe a case of multiple eruptive nevi of the palms and soles in association with immunosuppression, and the potential underlying mechanisms promoting such nevogenesis are explored. Although both the absolute number of nevi and presence of dysplastic nevi have been correlated with an increased relative risk of melanoma, actual risk of melanoma in patients with eruptive nevi is unknown.

Section snippets

Case report

A 25-year-old woman presented with multiple asymptomatic brown macules on the palms and soles that had initially appeared rapidly over the course of a few months during the time she was taking prednisone and azathioprine for active Crohn's disease. At the onset of her lesions, she had been using a tanning bed two to three times per week for several weeks. The patient denied any noticeable changes in preexisting lesions or any further appearance of new lesions after the original outbreak (5

Discussion

The sudden eruption of atypical and benign melanocytic nevi has been associated with a number of disease states and primary skin conditions. Blistering skin diseases account for the largest body of literature on generalized eruptive nevi, with associations reported for erythema multiforme,2, 3 Stevens-Johnson syndrome,4, 5 toxic epidermal necrolysis,3, 4, 6 epidermolysis bullosa,7, 8, 9 and blisters induced by mustard gas.¹⁰ The nevi are generally reported to appear in the weeks to months after

References (68)

K. Soltani et al.
Eruptive nevocytic nevi following erythema multiforme
J Am Acad Dermatol
(1979)
T. Shoji et al.
Eruptive melanocytic nevi after Stevens-Johnson syndrome
J Am Acad Dermatol
(1997)
J.W. Bauer et al.
Large melanocytic nevi in hereditary epidermolysis bullosa
J Am Acad Dermatol
(2001)
A. Firooz et al.
Eruptive melanocytic nevi and cherry angiomas secondary to exposure to sulfur mustard gas
J Am Acad Dermatol
(1999)
C.H. Smith et al.
Excess melanocytic nevi in children with renal allografts
J Am Acad Dermatol
(1993)
J.J. Grob et al.
Excess of nevi related to immunodeficiency: a study in HIV-infected patients and renal transplant recipients
J Invest Dermatol
(1996)
S. Richert et al.
Widespread eruptive dermal and atypical melanocytic nevi in association with chronic myelocytic leukemia: case report and review of the literature
J Am Acad Dermatol
(1996)
J.W. Kelly et al.
Sunlight: a major factor associated with the development of melanocytic nevi in Australian schoolchildren
J Am Acad Dermatol
(1994)
S. Darlington et al.
Longitudinal study of melanocytic nevi in adolescents
J Am Acad Dermatol
(2002)
Y. Harth et al.
Influence of cumulative sun exposure on the prevalence of common acquired nevi
J Am Acad Dermatol
(1992)

E. Healy et al.

Skin type, melanoma, and melanocortin 1 receptor variants

J Invest Dermatol

(1999)

M. van der Kraan et al.

Expression of melanocortin receptors and pro-opiomelanocortin in the rat spinal cord in relation to neurotrophic effects of melanocortins

Brain Res Mol Brain Res

(1999)

N. Hatta et al.

Expression, candidate gene, and population studies of the melanocortin 5 receptor

J Invest Dermatol

(2001)

I. Suzuki et al.

Agouti signaling protein inhibits melanogenesis and the response of human melanocytes to alpha-melanotropin

J Invest Dermatol

(1997)

E.A. Holly et al.

Number of melanocytic nevi as a major risk factor for malignant melanoma

J Am Acad Dermatol

(1987)

R.M. MacKie et al.

Personal risk-factor chart for cutaneous melanoma

Lancet

(1989)

C. Garbe et al.

Risk factors for developing cutaneous melanoma and criteria for identifying persons at risk: multicenter case-control study of the Central Malignant Melanoma Registry of the German Dermatological Society

J Invest Dermatol

(1994)

G.C. Roush et al.

Independence of dysplastic nevi from total nevi in determining risk for nonfamilial melanoma

Prev Med

(1988)

C.M. Rowland Payne et al.

Wallace's line

Br J Dermatol

(1986)

J.D. Kirby et al.

Eruptive melanocytic naevi following severe bullous disease

Br J Dermatol

(1978)

A.W. Kopf et al.

Eruptive nevocytic nevi after severe bullous disease

Arch Dermatol

(1977)

G. Goerz et al.

Eruptive nevocytic nevi after Lyell's syndrome

Arch Dermatol

(1978)

C.M. Lanschuetzer et al.

Pathogenic mechanisms in epidermolysis bullosa naevi

Acta Derm Venereol

(2003)

G. Annicchiarico et al.

Eruptive, punctiform, acquired but large melanocytic nevi in recessive dystrophic epidermolysis bullosa

Eur J Pediatr Dermatol

(2000)

J.M. McGregor et al.

The development of excess numbers of melanocytic naevi in an immunosuppressed identical twin

Clin Exp Dermatol

(1991)

J. Szepietowski et al.

Excess benign melanocytic naevi in renal transplant recipients

Dermatology

(1997)

J.N. Bouwes Bavinck et al.

Chronic sun exposure and age are inversely associated with nevi in adult renal transplant recipients

J Invest Dermatol

(1996)

M. Duvic et al.

Eruptive dysplastic nevi associated with human immunodeficiency virus infection

Arch Dermatol

(1989)

I. Betlloch et al.

Eruptive melanocytic nevi in human immunodeficiency virus infection

Int J Dermatol

(1991)

V. Gallais et al.

Acral hyperpigmented macules and longitudinal melanonychia in AIDS patients

Br J Dermatol

(1992)

B.R. Hughes et al.

Excess benign melanocytic naevi after chemotherapy for malignancy in childhood

BMJ

(1989)

P.E. de Wit et al.

Prevalence of naevocytic naevi after chemotherapy for childhood cancer

Med Pediatr Oncol

(1990)

K. Heyne et al.

Pigmented naevi after therapy of leukaemia (ALL) in a monozygotic twin

Eur J Pediatr

(1984)

T. Bogenrieder et al.

Eruptive multiple lentigo-maligna-like lesions in a patient undergoing chemotherapy with an oral 5-fluorouracil prodrug for metastasizing colorectal carcinoma: a lesson for the pathogenesis of malignant melanoma?

Dermatology

(2002)

Cited by (41)

Drug-Induced Eruptive Melanocytic Nevi
2017, Actas Dermo-Sifiliograficas
Capecitabine induced hyperpigmentation, a report of 2 different clinical presentations
2017, Piel
Eruptive nevi associated with medications (ENAMs)
2016, Journal of the American Academy of Dermatology
Citation Excerpt :
They often present in 1 of 3 distributions: (1) palmoplantar localized, (2) localized to trunk and proximal extremities, or (3) diffuse. A strong predilection for the palms and soles has been observed.4,39,94 This is in contrast to sporadic melanocytic nevi that appear to develop less frequently at acral sites.95
Eruptive melanocytic nevi have been reported in association with severe blistering diseases, renal transplantation, malignancy, AIDS, and medications. Eruptive nevi associated with medications have been reported with increasing frequency. Of particular interest are eruptive nevi associated with medications developing in association with biologic therapies, which we anticipate will continue to become more common as use of these medications continues to increase. We searched the databases PubMed/MEDLINE, Cochrane, and Cumulative Index to Nursing and Allied Health Literature for associated medications using the terms “eruptive nevi,” “melanocytic + medications,” and “nevi + medications” for relevant articles. We report the summary of our findings, which were used in defining what constitutes an eruptive nevi associated with medication and developing a classification system by medication type.
Dermoscopic changes in melanocytic nevi in patients receiving immunosuppressive and biologic treatments: Results of a prospective case-control study
2015, Journal of the American Academy of Dermatology
The immune system restrains benign melanocytic lesions, however the relationship between immunosuppression and changes in nevi is not known.
We sought to investigate the development of new nevi in patients using immunosuppressive agents, to evaluate any size or dermoscopic changes in existent nevi, and to evaluate any risk of developing melanoma.
There were 266 melanocytic lesions in 103 patients undergoing immunosuppressive therapy and 180 melanocytic lesions matched for age, sex, race, and Fitzpatrick skin type in 60 healthy control subjects.
Nevus counts increased from baseline in the treatment group (P < .001) as did nevus size (P = .046) but the increase compared with the control group only remained statistically significant for nevus numbers (P = .001). There was a statistically significant appearance of dermoscopic changes in the nevi of immunosuppressed patients compared with healthy control subjects (P < .001). Ten lesions were excised including 6 because of significant dermoscopic change during treatment and all were benign.
Follow-up duration was short and the number of patients was small.
Immunosuppressive therapy was associated with increased nevus counts and changed dermoscopic appearance but as none of the changed and subsequently excised nevi were malignant, continued monitoring for invasive features is a reasonable alternative to excision.
Pigmentary disorders induced by anticancer agents. Part I: Chemotherapy
2013, Annales de Dermatologie et de Venereologie
L’apparition d’une hyperpigmentation au cours des chimiothérapies est un des effets indésirables dermatologiques les plus fréquemment constatés avec ces traitements. Elle peut survenir avec de nombreuses molécules, de façon localisée ou diffuse, apparaître d’emblée pigmentée ou faire suite à des lésions inflammatoires, et concerner aussi bien la peau que les muqueuses ou l’appareil unguéal. Si leur incidence est élevée en pratique clinique, ces hyperpigmentations n’ont été en fait que rarement individualisées et caractérisées. Nous décrivons ici les principales caractéristiques cliniques, histologiques et physiopathologiques de ces hyperpigmentations induites, les molécules chimiothérapeutiques les plus souvent impliquées, les atteintes par site anatomique et les formes cliniques les plus spécifiques comme la dermatose flagellée à la bléomycine, les hyperpigmentations supraveineuses serpigineuses ou réticulées et les nævus éruptifs.
The occurrence of hyperpigmentation during chemotherapy is one of the most frequent dermatological adverse events observed with these drugs. It may arise with numerous anticancer agents, and can be either localized or diffuse, occurring either immediately or after inflammatory dermatological lesions. Nails, mucosa and skin may all be affected. Though the incidence is high in clinical practice, such drug-induced hyperpigmentation has been only rarely individualized and characterized. Herein we describe the main clinical, histological and pathophysiological characteristics of these lesions and the most frequently incriminated chemotherapeutic agents, as well as the anatomical areas involved and the most specific clinical patterns such as flagellate dermatitis, reticulate or serpentine supravenous hyperpigmentation and eruptive naevi.
Two cases of generalized eruptive lentiginosis in cutaneous T-cell lymphoma following mogamulizumab treatment
2022, International Journal of Dermatology

View all citing articles on Scopus

This supplement is made possible through the generous support of Stiefel Laboratories for the American Academy of Dermatology.

Funding sources: None.

Conflicts of interest: None identified.

Presented in oral form (in part) at the Annual American Academy of Dermatology meeting, Washington, DC, February 2004.

View full text

Case ReportEruptive nevi of the palms and soles

Section snippets

Case report

Discussion

J Am Acad Dermatol

J Am Acad Dermatol

J Am Acad Dermatol

J Am Acad Dermatol

J Am Acad Dermatol

J Invest Dermatol

J Am Acad Dermatol

J Am Acad Dermatol

J Am Acad Dermatol

J Am Acad Dermatol

J Invest Dermatol

Brain Res Mol Brain Res

J Invest Dermatol

J Invest Dermatol

J Am Acad Dermatol

Lancet

J Invest Dermatol

Prev Med

Wallace's line

Br J Dermatol

Eruptive melanocytic naevi following severe bullous disease

Br J Dermatol

Eruptive nevocytic nevi after severe bullous disease

Arch Dermatol

Eruptive nevocytic nevi after Lyell's syndrome

Arch Dermatol

Pathogenic mechanisms in epidermolysis bullosa naevi

Acta Derm Venereol

Eruptive, punctiform, acquired but large melanocytic nevi in recessive dystrophic epidermolysis bullosa

Eur J Pediatr Dermatol

The development of excess numbers of melanocytic naevi in an immunosuppressed identical twin

Clin Exp Dermatol

Excess benign melanocytic naevi in renal transplant recipients

Dermatology

Chronic sun exposure and age are inversely associated with nevi in adult renal transplant recipients

J Invest Dermatol

Eruptive dysplastic nevi associated with human immunodeficiency virus infection

Arch Dermatol

Eruptive melanocytic nevi in human immunodeficiency virus infection

Int J Dermatol

Acral hyperpigmented macules and longitudinal melanonychia in AIDS patients

Br J Dermatol

Excess benign melanocytic naevi after chemotherapy for malignancy in childhood

BMJ

Prevalence of naevocytic naevi after chemotherapy for childhood cancer

Med Pediatr Oncol

Pigmented naevi after therapy of leukaemia (ALL) in a monozygotic twin

Eur J Pediatr

Eruptive multiple lentigo-maligna-like lesions in a patient undergoing chemotherapy with an oral 5-fluorouracil prodrug for metastasizing colorectal carcinoma: a lesson for the pathogenesis of malignant melanoma?

Dermatology

Case Report
Eruptive nevi of the palms and soles